Use of cct020312 as a medicament for treating breast cancer or prostate cancer

Abstract

The application belongs to the technical field of biological medicine, and relates to application of CCT020312 as a drug for treating cancer, in particular to application of CCT020312 as a drug for treating breast cancer or prostate cancer. CCT020312 can activate the PERK / eIF2alpha / ATF4 signal pathway, and simultaneously down-regulate AR expression, inhibit the PI3K / AKT / mTOR signal pathway, promote cell cycle G1 phase arrest and cell autophagy, and induce cell apoptosis, so as to inhibit the occurrence and development of prostate cancer and breast cancer. CCT020312 can provide a new strategy and idea for targeted treatment of androgen receptor-dependent refractory tumors, and can be applied to medical practice for targeted treatment of prostate cancer and breast cancer.

Images